Low Intensity Contact Ultrasound Implant 

Medical Applications

After the surgical resection of brain tumors, treatments using chemotherapy are typically administered. Unfortunately, most drug molecules barely penetrate into the brain tissue due to the blood-brain barrier (BBB).

The SonoCloud® medical device allows for a temporary disruption of the BBB and thus an increase in the intracerebral bioavailability of chemotherapeutic agents. It can in principle be used for the treatment of primary brain tumors (gliomas, glioblastomas, astrocytomas, …) as well as secondary brain tumors (metastases). The combined annual incidence in Europe and the USA is more than 250,000 patients for these indications.

A phase 1/2a clinical trial has been started to study the transient opening of the BBB with the SonoCloud® before administration of chemotherapy in patients with recurrent glioblastoma. In the long term, the SonoCloud® system can be used for other disorders for which the BBB limits the efficacy of drug therapies (neurodegenerative diseases such as Alzheimer’s).

The SonoCloud® Treatment

The SonoCloud® medical device is implanted in the skull, normally following a surgical resection of the tumor. If the patient cannot be operated on, the SonoCloud® can be implanted in a burr hole performed for a diagnostic biopsy or during a special surgical act under local anesthesia. After implantation, the skin is used to recover the implant. The implant is activated before each chemotherapy session using a transdermal needle that connects the implant to an external generator. The connection to the implant can be performed by a nurse. The ultrasound is emitted directly to the brain tissue, without having to pass the skull, to temporarily open the blood-brain barrier. Finally, even large molecules can be effectively delivered to the brain after disruption of the BBB.

chien BHE 

The figure shows the opening of the blood-brain barrier using the SonoCloud® in an animal model. Note the contrast enhancement in the T1w MR image, which shows the region of BBB disruption. After 6 hours, the BBB integrity is restored.


  • unnamed-2

  • News CarThera

    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.

    ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

    Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

    Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at and come to Booth 527 at the France Pavilion.